Clinical Trial Update: Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

View source ↗

Summary

A completed clinical trial update evaluating Ribomustin (bendamustine) as second-line therapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ribomustin (bendamustine)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Lymphoma, Non-Hodgkin | Status: COMPLETED